These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 15501973)

  • 21. Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells.
    Li B; He X; Pang X; Zhang H; Chen J; Chen W
    Scand J Immunol; 2004 Nov; 60(5):506-13. PubMed ID: 15541044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
    Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
    Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
    Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
    Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
    Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
    Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry.
    Zhou M; Peng JR; Zhang HG; Wang HX; Zhong ZH; Pan XY; Chen WF; Leng XS
    Immunol Lett; 2005 Jun; 99(1):113-21. PubMed ID: 15885805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes.
    Godard B; Gazagne A; Gey A; Baptiste M; Vingert B; Pegaz-Fiornet B; Strompf L; Fridman WH; Glotz D; Tartour E
    Hum Immunol; 2004 Nov; 65(11):1307-18. PubMed ID: 15556681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E; Karbach J; Gnjatic S; Neumann A; Bender A; Valmori D; Ayyoub M; Ritter E; Ritter G; Jäger D; Panicali D; Hoffman E; Pan L; Oettgen H; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14453-8. PubMed ID: 16984998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
    Whiteside TL; Zhao Y; Tsukishiro T; Elder EM; Gooding W; Baar J
    Clin Cancer Res; 2003 Feb; 9(2):641-9. PubMed ID: 12576430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
    Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.